Business NewsPR NewsWire • Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin...

View More : https://www.prnewswire.com:443/news-releases/vicore-pharmas-drug-candidate-c21-dilates-peripheral-resistance-vessels-in-...
Releted News by prnewswire
Over $ 500 Million Growth in Global Anti-Fatigue Mat Market 2021-2025 | Includes Insights on Key Products Offered by Major Vendors | Technavio
FinVolution Group Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results
Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR
Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease